Antharis Therapeutics, Inc.
PrivateLast Round
Series A
Jul 14, 2022
Total Funding Raised
$48.2M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Antharis Therapeutics, Inc. operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series A round in July 2022.
Antharis Therapeutics, Inc. is a biotechnology company that develops monoclonal antibodies and antibody-drug conjugates to treat cancer and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antharis Therapeutics, Inc. Comparables
Compare Antharis Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Abalone Bio | 80% | |
| Elemental Biologics | 79% | |
| Catena Biosciences | 79% |
For institutional investors. Book with your work email.
Antharis Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 14, 2022 | ||||
| Seed | Dec 1, 2020 |
For institutional investors. Book with your work email.
Antharis Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Yazbeck & Co. | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 636% MoM.
- Jun 26, 2026
Grew 25% QoQ, from 16 to 20 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 16, 2026
On Jun 15th '26, Antharis Therapeutics, Inc. plans to develop novel dual-payload ADCs targeting GI cancers with Lonza under an exclusive, target-specific licensing agreement that combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering and target biology expertise; its lead program is about to enter the clinic.
For institutional investors. Book with your work email.
Antharis Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Antharis Therapeutics, Inc.'s valuation, stock price, and market status.
Is Antharis Therapeutics, Inc. a public or private company?
Antharis Therapeutics, Inc. is a private company.
What is the current stock price of Antharis Therapeutics, Inc.?
Antharis Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Antharis Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Antharis Therapeutics, Inc. worth (valuation)?
Valuation information for Antharis Therapeutics, Inc. is not publicly available.
Can I buy Antharis Therapeutics, Inc. stock?
Antharis Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Antharis Therapeutics, Inc.'s last funding round?
Antharis Therapeutics, Inc.'s most recent funding round was Series A on July 14, 2022.
Who are the main investors in Antharis Therapeutics, Inc.?
Key investors in Antharis Therapeutics, Inc. include Yazbeck & Co..
Will Antharis Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Antharis Therapeutics, Inc..
How can I track Antharis Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Antharis Therapeutics, Inc.'s shares on secondary markets.